A high degree of sensitization to human leukocyte antigen requires more intensive induction therapy; however, this increases vulnerability to opportunistic infections following kidney transplantation. Although recent studies have suggested that combined induction therapy with antithymocyte globulin and rituximab would be more effective in highly sensitized kidney recipients, we experienced a case of near-fatal invasive pulmonary aspergillosis 2 months after combined induction and early rejection therapy for graft dysfunction. Fortunately, the patient recovered with intensive antifungal treatment and lung lobectomy for a necrotic cavity. Antifungal prophylaxis should be considered in cases undergoing intensive induction therapy.
INTRODUCTION
The incidence rate of IPA after KTP is 0.4%, in comparison with 1.3% and 1.9% after heart and liver transplantation, respectively (3) . Nevertheless, KTP recipients have the highest burden of posttransplant IPA because KTP is the most frequently performed transplant procedure worldwide. Sixand 12-week survival rates for IPA after KTP were 68.8% and 60.7%, respectively, and 22.1% of survivors experienced graft loss (4) . We report a case of near-fatal early IPA 2 months after combined induction therapy using rituximab and antithymocyte globulin, in addition to early rejection therapy for graft dysfunction soon after deceased donor KTP. The patient recovered with intensive antifungal treatment and lung lobectomy for a necrotic cavity, and had good allograft function without intermittent hemodialysis.
CASE REPORT
A 57-year-old woman with diabetes mellitus and endstage renal disease had been on peritoneal dialysis for 4 years, and was changed to intermittent hemodialysis 1 year prior to surgery. She underwent deceased donor KTP with combination induction therapy using rituximab (300 mg/m 2 ) and antithymocyte globulin (1.5 mg/kg/day for 4 days) because of high-grade sensitization to HLA (PRA titer: class I 22%, class II 51%); she was given tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression. Four did not identify a lesion, bronchoalveolar lavage (BAL) and sputum cytology also found Aspergillus. We started voriconazole as an antifungal agent and reduced tacrolimus from 7 mg/day (3.5 mg twice daily) to 2 mg/day. The tacrolimus level was 15.8 ng/mL, so we gradually reduced all immunosuppressant agents. However, her chest X-ray showed a worsening pleural effusion. The effusion was treated by percutaneous drain insertion and the exudate was analyzed. We then added micafungin. However, she needed intubation and mechanical ventilation in the intensive care unit for 5 days, and all immunosuppressive agents were stopped. The Cr decreased from 1.7 to 1.08. As soon as her condition improved, we restarted tacrolimus 0.5 mg and added mycophenolate mofetil and prednisolone 5 mg on day 20. On day 29, the pleural effusion was found to be increas- ing rapidly, and we performed a percutaneous needle biopsy that was reported as necrotizing granulomatous inflammation with Aspergillus (Fig. 2) . Therefore, we diagnosed primary antifungal therapy failure and changed to secondary agents, including combined amphotericin B and anidulafungin; we again reduced and gradually stopped the immunosuppressive agents, and only used maintenance prednisolone 7.5 mg. Thereafter, Cr increased from 1.08 to 3.6 mg/dL, and graft function worsened; we restarted intermittent hemodialysis for fluid volume control. On day 82, follow-up chest CT showed an increasing right loculated pleural effusion (Fig. 1B) and a necrotic cavitary lesion, with the potential for development of a bronchopleural fistula (Fig. 1C) . On day 101, right lower lung lobectomy was performed, and an Aspergillus lesion was removed; we stopped antifungal agents 40 days after surgery. Graft function improved and Cr decreased to 1.4 mg/dL, with no further need for hemodialysis (Fig. 3) . A low tacrolimus level (1.5 to 2.9 ng/mL) was maintained. 
